144 related articles for article (PubMed ID: 37993023)
1. CSF1 expression in xanthogranulomatous epithelial tumor/keratin-positive giant cell-rich tumor.
Dehner CA; Lo YC; Chopra S; Demicco EG; He K; Hirbe AC; Folpe AL; Chrisinger JSA
Hum Pathol; 2024 Jan; 143():1-4. PubMed ID: 37993023
[TBL] [Abstract][Full Text] [Related]
2. Xanthogranulomatous epithelial tumors and keratin-positive giant cell-rich soft tissue tumors: two aspects of a single entity with frequent HMGA2-NCOR2 fusions.
Dehner CA; Baker JC; Bell R; Dickson BC; Schmidt RE; Demicco EG; Chrisinger JSA
Mod Pathol; 2022 Nov; 35(11):1656-1666. PubMed ID: 35690644
[TBL] [Abstract][Full Text] [Related]
3. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors.
Thangaiah JJ; Koepplin JW; Folpe AL
Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245
[TBL] [Abstract][Full Text] [Related]
4. Keratin-positive giant cell-rich tumors of soft tissue with HMGA2::NCOR2 fusions.
Weigelt MA; Azzato EM; Habermehl GK; Billings SD; Ko JS; Fritchie KJ
J Cutan Pathol; 2023 Nov; 50(11):977-982. PubMed ID: 37496152
[TBL] [Abstract][Full Text] [Related]
5. Xanthogranulomatous Epithelial Tumors and Keratin-Positive Giant Cell Rich Tumors of Soft Tissue and Bone: Two Sides of the Same Coin.
Folpe AL
Surg Pathol Clin; 2024 Mar; 17(1):57-64. PubMed ID: 38278607
[TBL] [Abstract][Full Text] [Related]
6. Keratin-Positive Giant Cell-Rich Tumor: A Review and Update.
Nishio J; Nakayama S; Koga K; Aoki M
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792018
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue.
Sugita S; Takenami T; Kido T; Aoyama T; Hosaka M; Segawa K; Sugawara T; Fujita H; Shimizu J; Murahashi Y; Emori M; Hasegawa T
Diagn Pathol; 2022 Nov; 17(1):88. PubMed ID: 36320082
[TBL] [Abstract][Full Text] [Related]
8. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
West RB; Rubin BP; Miller MA; Subramanian S; Kaygusuz G; Montgomery K; Zhu S; Marinelli RJ; De Luca A; Downs-Kelly E; Goldblum JR; Corless CL; Brown PO; Gilks CB; Nielsen TO; Huntsman D; van de Rijn M
Proc Natl Acad Sci U S A; 2006 Jan; 103(3):690-5. PubMed ID: 16407111
[TBL] [Abstract][Full Text] [Related]
9. Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel
Mejbel H; Siegal GP; Wei S
Int J Surg Pathol; 2022 May; 30(3):335-338. PubMed ID: 34657489
[TBL] [Abstract][Full Text] [Related]
10. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors.
Ho J; Peters T; Dickson BC; Swanson D; Fernandez A; Frova-Seguin A; Valentin MA; Schramm U; Sultan M; Nielsen TO; Demicco EG
Genes Chromosomes Cancer; 2020 Feb; 59(2):96-105. PubMed ID: 31469468
[TBL] [Abstract][Full Text] [Related]
11. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
[TBL] [Abstract][Full Text] [Related]
12. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides.
Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB
Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089
[TBL] [Abstract][Full Text] [Related]
13. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
Tap WD; Wainberg ZA; Anthony SP; Ibrahim PN; Zhang C; Healey JH; Chmielowski B; Staddon AP; Cohn AL; Shapiro GI; Keedy VL; Singh AS; Puzanov I; Kwak EL; Wagner AJ; Von Hoff DD; Weiss GJ; Ramanathan RK; Zhang J; Habets G; Zhang Y; Burton EA; Visor G; Sanftner L; Severson P; Nguyen H; Kim MJ; Marimuthu A; Tsang G; Shellooe R; Gee C; West BL; Hirth P; Nolop K; van de Rijn M; Hsu HH; Peterfy C; Lin PS; Tong-Starksen S; Bollag G
N Engl J Med; 2015 Jul; 373(5):428-37. PubMed ID: 26222558
[TBL] [Abstract][Full Text] [Related]
14. Giant Cell Tumors With HMGA2::NCOR2 Fusion : Clinicopathologic, Molecular, and Epigenetic Study of a Distinct Entity.
Perret R; Malaka Z; Velasco V; Llamas-Gutierrez F; Ropars M; Linck PA; Hostein I; Azmani R; Valo I; Galmiche L; Moreau A; de Pinieux G; Michot A; Bochaton D; Coindre JM; Le Loarer F
Am J Surg Pathol; 2023 Jul; 47(7):801-811. PubMed ID: 37170907
[TBL] [Abstract][Full Text] [Related]
15. Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors.
Agaimy A; Michal M; Stoehr R; Ferrazzi F; Fabian P; Michal M; Franchi A; Haller F; Folpe AL; Kösemehmetoğlu K
Mod Pathol; 2021 Aug; 34(8):1507-1520. PubMed ID: 33742141
[TBL] [Abstract][Full Text] [Related]
16. A novel colony-stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor.
Lipplaa A; Meijer D; van de Sande MAJ; Gelderblom H; Bovée JVMG; Mei H; Szuhai K
Genes Chromosomes Cancer; 2023 Apr; 62(4):223-230. PubMed ID: 36504457
[TBL] [Abstract][Full Text] [Related]
17. Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations.
Tsuda Y; Hirata M; Katayama K; Motoi T; Matsubara D; Oda Y; Fujita M; Kobayashi H; Kawano H; Nishida Y; Sakai T; Okuma T; Goto T; Ogura K; Kawai A; Ae K; Anazawa U; Suehara Y; Iwata S; Miyano S; Imoto S; Shibata T; Nakagawa H; Yamaguchi R; Tanaka S; Matsuda K
Int J Cancer; 2019 Dec; 145(12):3276-3284. PubMed ID: 31107544
[TBL] [Abstract][Full Text] [Related]
18. Malignant Tenosynovial Giant Cell Tumor: The True "Synovial Sarcoma?" A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes.
Al-Ibraheemi A; Ahrens WA; Fritchie K; Dong J; Oliveira AM; Balzer B; Folpe AL
Mod Pathol; 2019 Feb; 32(2):242-251. PubMed ID: 30206409
[TBL] [Abstract][Full Text] [Related]
19. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
[TBL] [Abstract][Full Text] [Related]
20. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor.
Tap WD; Healey JH
Tumour Biol; 2022; 44(1):239-248. PubMed ID: 36502356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
